Logo image of APYX

APYX MEDICAL CORP (APYX) Stock Fundamental Analysis

USA - NASDAQ:APYX - US03837C1062 - Common Stock

2.9 USD
-0.13 (-4.29%)
Last: 10/23/2025, 4:30:01 PM
Fundamental Rating

2

Overall APYX gets a fundamental rating of 2 out of 10. We evaluated APYX against 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of APYX have multiple concerns. APYX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year APYX has reported negative net income.
In the past year APYX has reported a negative cash flow from operations.
APYX had negative earnings in each of the past 5 years.
In the past 5 years APYX always reported negative operating cash flow.
APYX Yearly Net Income VS EBIT VS OCF VS FCFAPYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

1.2 Ratios

The Return On Assets of APYX (-29.66%) is comparable to the rest of the industry.
The Return On Equity of APYX (-237.96%) is worse than 74.21% of its industry peers.
Industry RankSector Rank
ROA -29.66%
ROE -237.96%
ROIC N/A
ROA(3y)-34.86%
ROA(5y)-28.54%
ROE(3y)-98.96%
ROE(5y)-68.76%
ROIC(3y)N/A
ROIC(5y)N/A
APYX Yearly ROA, ROE, ROICAPYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

APYX has a better Gross Margin (61.63%) than 63.16% of its industry peers.
In the last couple of years the Gross Margin of APYX has declined.
APYX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.12%
GM growth 5Y-2.02%
APYX Yearly Profit, Operating, Gross MarginsAPYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

More info and screens

3

2. Health

2.1 Basic Checks

APYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
APYX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for APYX has been increased compared to 5 years ago.
Compared to 1 year ago, APYX has a worse debt to assets ratio.
APYX Yearly Shares OutstandingAPYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
APYX Yearly Total Debt VS Total AssetsAPYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

APYX has an Altman-Z score of 0.20. This is a bad value and indicates that APYX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.20, APYX perfoms like the industry average, outperforming 43.68% of the companies in the same industry.
A Debt/Equity ratio of 4.74 is on the high side and indicates that APYX has dependencies on debt financing.
APYX's Debt to Equity ratio of 4.74 is on the low side compared to the rest of the industry. APYX is outperformed by 87.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.74
Debt/FCF N/A
Altman-Z 0.2
ROIC/WACCN/A
WACC9.21%
APYX Yearly LT Debt VS Equity VS FCFAPYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 4.72 indicates that APYX has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.72, APYX is doing good in the industry, outperforming 75.79% of the companies in the same industry.
A Quick Ratio of 3.95 indicates that APYX has no problem at all paying its short term obligations.
APYX's Quick ratio of 3.95 is fine compared to the rest of the industry. APYX outperforms 74.21% of its industry peers.
Industry RankSector Rank
Current Ratio 4.72
Quick Ratio 3.95
APYX Yearly Current Assets VS Current LiabilitesAPYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

APYX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.12%, which is quite impressive.
The Revenue has decreased by -5.15% in the past year.
Measured over the past years, APYX shows a quite strong growth in Revenue. The Revenue has been growing by 11.24% on average per year.
EPS 1Y (TTM)45.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.63%
Revenue 1Y (TTM)-5.15%
Revenue growth 3Y-0.29%
Revenue growth 5Y11.24%
Sales Q2Q%-6.39%

3.2 Future

APYX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.24% yearly.
Based on estimates for the next years, APYX will show a very strong growth in Revenue. The Revenue will grow by 41.40% on average per year.
EPS Next Y43.67%
EPS Next 2Y16.64%
EPS Next 3Y14.8%
EPS Next 5Y18.24%
Revenue Next Year5.76%
Revenue Next 2Y5.36%
Revenue Next 3Y6.31%
Revenue Next 5Y41.4%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
APYX Yearly Revenue VS EstimatesAPYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
APYX Yearly EPS VS EstimatesAPYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APYX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APYX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APYX Price Earnings VS Forward Price EarningsAPYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APYX Per share dataAPYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as APYX's earnings are expected to grow with 14.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.64%
EPS Next 3Y14.8%

More info and screens

0

5. Dividend

5.1 Amount

APYX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APYX MEDICAL CORP

NASDAQ:APYX (10/23/2025, 4:30:01 PM)

2.9

-0.13 (-4.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners42.84%
Inst Owner Change0.85%
Ins Owners14.55%
Ins Owner Change0%
Market Cap109.68M
Revenue(TTM)46.51M
Net Income(TTM)-17259000
Analysts77.78
Price Target4.08 (40.69%)
Short Float %0.73%
Short Ratio3.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.88%
Min EPS beat(2)5.46%
Max EPS beat(2)18.3%
EPS beat(4)4
Avg EPS beat(4)19.07%
Min EPS beat(4)5.46%
Max EPS beat(4)26.47%
EPS beat(8)5
Avg EPS beat(8)1.82%
EPS beat(12)6
Avg EPS beat(12)-3.78%
EPS beat(16)9
Avg EPS beat(16)1.59%
Revenue beat(2)0
Avg Revenue beat(2)-3.11%
Min Revenue beat(2)-4.69%
Max Revenue beat(2)-1.52%
Revenue beat(4)1
Avg Revenue beat(4)-0.77%
Min Revenue beat(4)-4.69%
Max Revenue beat(4)4.14%
Revenue beat(8)3
Avg Revenue beat(8)-2.89%
Revenue beat(12)4
Avg Revenue beat(12)-4.23%
Revenue beat(16)7
Avg Revenue beat(16)-1.16%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2.5%
EPS NQ rev (3m)-6.03%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.78%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)2.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.36
P/FCF N/A
P/OCF N/A
P/B 15.12
P/tB 15.12
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS1.23
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.66%
ROE -237.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.63%
FCFM N/A
ROA(3y)-34.86%
ROA(5y)-28.54%
ROE(3y)-98.96%
ROE(5y)-68.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.12%
GM growth 5Y-2.02%
F-Score3
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 4.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 129.14%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.72
Quick Ratio 3.95
Altman-Z 0.2
F-Score3
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)103.68%
Cap/Depr(5y)91.24%
Cap/Sales(3y)1.6%
Cap/Sales(5y)1.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.63%
EPS Next Y43.67%
EPS Next 2Y16.64%
EPS Next 3Y14.8%
EPS Next 5Y18.24%
Revenue 1Y (TTM)-5.15%
Revenue growth 3Y-0.29%
Revenue growth 5Y11.24%
Sales Q2Q%-6.39%
Revenue Next Year5.76%
Revenue Next 2Y5.36%
Revenue Next 3Y6.31%
Revenue Next 5Y41.4%
EBIT growth 1Y45.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.7%
EBIT Next 3Y19.61%
EBIT Next 5Y28.09%
FCF growth 1Y41.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.97%
OCF growth 3YN/A
OCF growth 5YN/A